

LETTER

Mutation screening of *RAD51C* in male breast cancer patients

Valentina Silvestri¹, Piera Rizzolo¹, Mario Falchetti¹, Ines Zanna², Giovanna Masala², Domenico Palli² and Laura Ottini^{*1}

See related research by Akbari et al., <http://breast-cancer-research.com/content/12/4/404>

We read with great interest the paper by Akbari and colleagues [1] in a recent issue of *Breast Cancer Research*. The authors reported on the absence of *RAD51C* mutations in 454 patients with *BRCA1/2*-negative familial breast cancer/ovarian cancer (BC/OC). In the initial report by Meindl and colleagues [2], *RAD51C* mutations were identified in 6 out of 480 patients with *BRCA1/2*-negative familial BC/OC. Interestingly, on the basis of histopathologic features, including intermediate grade (G2), estrogen receptor-positive (ER⁺), progesterone receptor-positive (PR⁺), and HER2-negative (HER2⁻) expression, *RAD51C*-associated BCs were found to be similar to *BRCA2*-associated BCs [2]. *BRCA2* is known to play a significant role in male BC (MBC); however, no occurrence of MBC was observed in the six *RAD51C* families described [2].

To investigate the role of *RAD51C* in MBC, we screened for *RAD51C* mutations in 97 MBC patients selected from our population-based series of 126 cases because they were previously found negative for *BRCA1/2*, *CHEK2*, *PALB2*, and *BRIP1* mutations [3,4]. Notably, 25.8% of cases showed a positive first-degree family history of BC or OC or both. The majority of MBCs were invasive ductal carcinomas (74.5%), G2 (53.5%), ER⁺ (90.7%), PR⁺ (82.6%), or HER2⁻ (85.4%). Overall, 66% of the MBCs showed an ER⁺/PR⁺/HER2⁻ phenotype. All patients provided informed consent to the study. We carried out mutation screening of the nine exons and intron/exon boundaries of *RAD51C* by high resolution melting (HRM) analysis, a rapid closed-tube mutation scanning method with high sensitivity and specificity. Cases displaying abnormal profiles were evaluated by direct sequencing. Primers are available upon request.

We found no truncating *RAD51C* mutations. We identified a novel intronic variant, *IVS3 c.738-16G>T*, in

1 out of 97 MBCs (1%). By *in silico* analysis, performed with Splice Site Prediction (Berkeley Drosophila Genome Project, Lawrence Berkeley National Laboratory, Berkeley, CA, USA) and NetGene 2 Server software (Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark), the *IVS3 c.738-16G>T* variant is predicted not to affect splicing. This variant was also identified in 2 out of 173 (1.2%) population controls examined. We also found a neutral polymorphic intronic variant, *IVS6 c.904+34T>C* (rs28363318), in 16 out of 97 (16.5%) MBCs.

Overall, our results, which are based on a relatively large MBC series, are consistent with the findings by Akbari and colleagues [1] and with data on 92 patients with hereditary gynecological cancer in which no deleterious *RAD51C* mutations were identified [5] and would suggest that the impact of *RAD51C* mutations on BC predisposition might be more limited than initially reported. In conclusion, we found no evidence that *RAD51C* mutations may contribute to MBC susceptibility. Further studies on larger MBC series are needed to confirm our findings.

Abbreviations

BC, breast cancer; ER, estrogen receptor; G2, intermediate grade; MBC, male breast cancer; OC, ovarian cancer; PR, progesterone receptor.

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

This letter was supported by a grant from Associazione Italiana per la Ricerca sul Cancro (AIRC IG 8713).

Author details

¹Department of Molecular Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, 00161 Rome, Italy; ²Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute - ISPO, Via Cosimo il Vecchio 2, 50139 Florence, Italy.

Published: 8 February 2011

References

1. Akbari MR, Tonin P, Foulkes WD, Ghadirian P, Tischkowitz M, Narod SA: ***RAD51C* germline mutations in breast and ovarian cancer patients.** *Breast Cancer Res* 2010, **12**:404.
2. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramsen J, Honisch E, Kubisch C,

*Correspondence: laura.ottini@uniroma1.it

¹Department of Molecular Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, 00161 Rome, Italy

Full list of author information is available at the end of the article

- Wichmann HE, Kast K, Deissler H, Engel C, Müller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H: **Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.** *Nat Genet* 2010, **42**:410-414.
3. Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Gulino A, Giannini G, Bianchi S, Sera F, Palli D: **BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy.** *Breast Cancer Res Treat* 2009, **116**:577-586.
 4. Silvestri V, Rizzolo P, Falchetti M, Zanna I, Masala G, Bianchi S, Palli D, Ottini L: **Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy.** *Breast Cancer Res Treat* 2010 Dec 17. [Epub ahead of print].
 5. Zheng Y, Zhang J, Hope K, Niu Q, Huo D, Olopade OI: **Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer.** *Breast Cancer Res Treat* 2010, **124**:857-861.

doi:10.1186/bcr2823

Cite this article as: Silvestri V, et al.: Mutation screening of RAD51C in male breast cancer patients. *Breast Cancer Research* 2011, **13**:404.